Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 12/20 | 0.50 |
| ▸ | PARP1 | P09874 | 9/20 | 0.50 |
| ▸ | FLT1 | P17948 | 3/20 | 0.49 |
| ▸ | FLT4 | P35916 | 3/20 | 0.49 |
| ▸ | CSF1R | P07333 | 2/20 | 0.49 |
| ▸ | KIT | P10721 | 2/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30453745 | 1.00 | HDAC1 (0.53) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL30452921 | 0.90 | KDR (0.54) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL588547 | 0.90 | KDR (0.54) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL30452644 | 0.85 | KDR (0.61) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL588581 | 0.85 | KDR (0.61) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL31672478 | 0.83 | KDR (0.51) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL10151205 | 0.83 | KDR (0.51) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL589306 | 0.82 | KDR (0.53) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL589388 | 0.82 | KDR (0.66) | LCKJAK3KDRPARP1FLT1 | |
| SCHEMBL30452580 | 0.82 | KDR (0.66) | LCKJAK3KDRPARP1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311825-B1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2015-10-07 | — | — | EP | claimed |
| EP-2311825-A1 | Pyrimidineamines as angiogenesis modulators | GlaxoSmithKline LLC (US) | 2011-04-20 | — | — | EP | claimed |
| US-7262203-B2 | Pyrimidineamines as angiogenesis modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-28 | — | — | US | claimed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | claimed |
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | claimed |
| EP-4599890-A2 | SUNITINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2025-08-13 | — | — | EP | disclosed |
| CN-113181362-B | Medicament for preventing and/or treating amyotrophic lateral sclerosis | 国立大学法人京都大学 | 2023-06-13 | — | — | CN | disclosed |
| CN-113181362-A | Agent for preventing and/or treating amyotrophic lateral sclerosis | 国立大学法人京都大学 | 2021-07-30 | — | — | CN | disclosed |
| EP-3789027-A1 | BOSUTINIB, SUNITINIB, TIVOZANIB, IMATINIB, NILOTINIB, REBASTINIB OR BAFETINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2021-03-10 | — | — | EP | disclosed |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-3246046-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2017-11-22 | — | — | EP | disclosed |
| EP-2311825-B1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| US-7262203-B2 | Pyrimidineamines as angiogenesis modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | disclosed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | disclosed |
| US-20070015756-A1 | Chemical compounds | NOVARTIS AG (CH) | 2007-01-18 | — | — | US | disclosed |
| US-7105530-B2 | inhibitors of vascular endothelial growth factor receptor-2 kinase; pazopanib and salts; for proliferative retinopathy; anticancer | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | disclosed |
| EP-1343782-A1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002059110-A1 | PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS | GLAXO GROUP LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242578-A1 | Pyrimidineamines as angiogenesis modulators | TYMS, TYMP, DPYD | HDAC1 4184/4885HDAC6 3978/4885HDAC3 4522/4885 |
| US-20070015756-A1 | Chemical compounds | KDR, FLT4, FLT1 | HDAC1 3892/4885HDAC6 3853/4885HDAC3 4193/4885 |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | WEE2, WEE1, ERBB2 | HDAC1 3365/4885HDAC6 1491/4885HDAC3 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.